TY - JOUR
T1 - Association of Obesity with Cardiovascular Risk Factors and Kidney Disease Outcomes in Primary Proteinuric Glomerulopathies
AU - Shah, Paras P.
AU - Brady, Tammy M.
AU - Meyers, Kevin E.C.
AU - O'Shaughnessy, Michelle M.
AU - Gibson, Keisha L.
AU - Srivastava, Tarak
AU - Zee, Jarcy
AU - Cattran, Daniel
AU - Tuttle, Katherine R.
AU - Gadegbeku, Crystal
AU - Glenn, Dorey
AU - Derebail, Vimal
AU - Smith, Abigail
AU - Wang, Chia Shi
AU - Gillespie, Brenda W.
AU - Bitzer, Markus
AU - Sethna, Christine B.
N1 - Funding Information:
The authors have no conflicts of interest to declare in relation to the submitted work. T.S. reports grants from Mallinckrodt Pharmaceuticals, grants from Bristol-Myers Squibb, and grants from Retrophin Inc., all outside the submitted work. K.G. reports personals fees from Reata and grants from Retrophin, all outside the submitted work. K.T. reports personal fees from Boehringer Ingelheim, fees from AstraZeneca, personal fees from Gilead, grants and fees from Goldfinch Bio, personal fees from Novo Nordisk, and personal fees from Bayer, all outside the submitted work. V.D. reports personal fees from Novartis and personal fees from Retrophin, all outside the submitted work.
Funding Information:
The Nephrotic Syndrome Study Network Consortium (NEPTUNE), U54-DK-083912, is a part of the National Institutes of Health (NIH) Rare Disease Clinical Research Network (RDCRN), supported through a collaboration between the Office of Rare Diseases Research (ORDR), NCATS, and the National Institute of Diabetes, Digestive, and Kidney Diseases. Additional funding and/or programmatic support for this project has also been provided by the University of Michigan, the NephCure Kidney International, and the Halpin Foundation. This work was also supported by the American Heart Association Grant in Aid 15GRNT25360029 (Sethna).
Publisher Copyright:
© 2021 S. Karger AG, Basel.
PY - 2021/5
Y1 - 2021/5
N2 - Background/Aims: Obesity is a known risk factor for cardiovascular disease and contributes to the development and progression of kidney disease. However, the specific influence of obesity on outcomes in primary glomerular disease has not been well characterized. Methods: In this prospective cohort study, data were from 541 participants enrolled in the Nephrotic Syndrome Study Network (NEPTUNE), between 2010 and 2019, at 23 sites across North America. Blood pressure, lipids, and kidney disease outcomes including complete proteinuria remission, kidney failure, and chronic kidney disease progression were evaluated. Data were analyzed using linear and logistic regression with generalized estimating equations and time-varying Cox regression with Kaplan-Meier plots. Results: The prevalence of obesity at baseline was 43.3% (N = 156) in adults and 37.6% (N = 68) in children. In adults, obesity was longitudinally associated with higher systolic BP (β = 6.49, 95% CI: 2.41, 10.56, p = 0.002), dyslipidemia (OR = 1.74, 95% CI: 1.30, 2.32, p < 0.001), triglycerides (β = 41.92, 95% CI: 17.12, 66.71, p = 0.001), and lower HDL (β = -6.92, 95% CI: -9.32, -4.51, p < 0.001). In children, obesity over time was associated with higher systolic BP index (β = 0.04, 95% CI: 0.02, 0.06, p < 0.001) and hypertension (OR = 1.43, 95% CI: 1.04, 1.98, p = 0.03). In both adults and children, obesity was associated with a significantly lower hazard of achieving complete remission of proteinuria (adult HR = 0.80, 95% CI: 0.69, 0.88, p < 0.001; pediatric HR = 0.72, 95% CI: 0.61, 0.84, p < 0.001). Conclusion: Obesity was associated with higher cardiovascular risk and less proteinuria remission from nephrotic syndrome in adults and children with proteinuric glomerulopathies. Weight-loss strategies may forestall cardiovascular disease and progressive kidney function decline in this high-risk patient group.
AB - Background/Aims: Obesity is a known risk factor for cardiovascular disease and contributes to the development and progression of kidney disease. However, the specific influence of obesity on outcomes in primary glomerular disease has not been well characterized. Methods: In this prospective cohort study, data were from 541 participants enrolled in the Nephrotic Syndrome Study Network (NEPTUNE), between 2010 and 2019, at 23 sites across North America. Blood pressure, lipids, and kidney disease outcomes including complete proteinuria remission, kidney failure, and chronic kidney disease progression were evaluated. Data were analyzed using linear and logistic regression with generalized estimating equations and time-varying Cox regression with Kaplan-Meier plots. Results: The prevalence of obesity at baseline was 43.3% (N = 156) in adults and 37.6% (N = 68) in children. In adults, obesity was longitudinally associated with higher systolic BP (β = 6.49, 95% CI: 2.41, 10.56, p = 0.002), dyslipidemia (OR = 1.74, 95% CI: 1.30, 2.32, p < 0.001), triglycerides (β = 41.92, 95% CI: 17.12, 66.71, p = 0.001), and lower HDL (β = -6.92, 95% CI: -9.32, -4.51, p < 0.001). In children, obesity over time was associated with higher systolic BP index (β = 0.04, 95% CI: 0.02, 0.06, p < 0.001) and hypertension (OR = 1.43, 95% CI: 1.04, 1.98, p = 0.03). In both adults and children, obesity was associated with a significantly lower hazard of achieving complete remission of proteinuria (adult HR = 0.80, 95% CI: 0.69, 0.88, p < 0.001; pediatric HR = 0.72, 95% CI: 0.61, 0.84, p < 0.001). Conclusion: Obesity was associated with higher cardiovascular risk and less proteinuria remission from nephrotic syndrome in adults and children with proteinuric glomerulopathies. Weight-loss strategies may forestall cardiovascular disease and progressive kidney function decline in this high-risk patient group.
KW - Body mass index
KW - Hypertension
KW - Nephrotic syndrome
KW - Obesity
KW - Pediatrics
KW - Proteinuria
UR - http://www.scopus.com/inward/record.url?scp=85102616592&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85102616592&partnerID=8YFLogxK
U2 - 10.1159/000513869
DO - 10.1159/000513869
M3 - Article
C2 - 33677435
AN - SCOPUS:85102616592
SN - 1660-8151
VL - 145
SP - 245
EP - 255
JO - Nephron
JF - Nephron
IS - 3
ER -